Replies to post #334128 on Anavex Life Sciences Corp (AVXL)

[bas2020]

For example, there are questions about travel and shopping.

I would think that questions which don't apply would be nulled out (not count either way).

[frrol]

Cortexyme's drug may be helpful to a PG+ population. Obviously that's where they'll focus their phase 3 design. They're gonna have to overcome concerns around the liver AEs. That's a pretty serious potential medical headwind. The company is downplaying it but regulators won't. (For conspiracists: the concerns wouldn't be because of 'FUD', corrupt BP pressure, FDA collusion, cabals, or other nonsense. It would be because of liver enzyme data.)

[WolfofMia]

Cortexyme Alz GAIN

I think you meant to say Cortexyme ALZ LOOSER**.

Also I think you should use PDD data not an open label trial on Alz, to judge 2-73 thus far.

Where we can see correlation (70 percent )between episodic memory to ADAS-COG11.

significant dose-dependent (p = 0.003) improvement of CDR system Episodic Memory. Not only is this significant for PDD treatment, but this measure has also been shown to be highly correlated (70%) with the Alzheimer’s Disease Assessment Scale–Cognitive score (ADAS-Cog),

https://seekingalpha.com/article/4452448-anavex-life-sciences-still-room-to-run

All I have to say, asides from I think we got this.